Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer

Article Properties
Cite
Palácová, Markéta. “Hormonal Therapy in Premenopausal Patients With SR-Positive, HER2-Negative Breast Cancer”. Onkologie, vol. 13, no. 1, 2019, pp. 24-28, https://doi.org/10.36290/xon.2019.005.
Palácová, M. (2019). Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. Onkologie, 13(1), 24-28. https://doi.org/10.36290/xon.2019.005
Palácová, Markéta. “Hormonal Therapy in Premenopausal Patients With SR-Positive, HER2-Negative Breast Cancer”. Onkologie 13, no. 1 (2019): 24-28. https://doi.org/10.36290/xon.2019.005.
Palácová M. Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. Onkologie. 2019;13(1):24-8.
Refrences
Title Journal Journal Categories Citations Publication Date
De-escalating and escalating treatments for early-stage breast cancer: the St.Gallen international expert consensus conference on the primary therapy of early breast cancer 2017
10.1016/S0140-6736(11)60993-8
10.1016/S0140-6736(11)60993-8
10.1200/JCO.2015.62.3504
10.1056/NEJMoa1701830
Citations
Title Journal Journal Categories Citations Publication Date
Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice Molecular Therapy
  • Technology: Chemical technology: Biotechnology
  • Science: Biology (General): Genetics
  • Medicine: Medicine (General)
  • Science: Biology (General): Genetics
  • Medicine: Medicine (General)
 54 2021
Citations Analysis
Category Category Repetition
Technology: Chemical technology: Biotechnology1
Science: Biology (General): Genetics1
Medicine: Medicine (General)1
The category Technology: Chemical technology: Biotechnology 1 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice and was published in 2021. The most recent citation comes from a 2021 study titled Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. This article reached its peak citation in 2021, with 1 citations. It has been cited in 1 different journals. Among related journals, the Molecular Therapy cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year